The present invention provides an MPHOSPH1-derived epitope peptide exhibiting cytotoxic T lymphocyte inducibility. The present invention also provides: a polynucleotide encoding said peptide； an antigen-presenting cell presenting said peptide； a cytotoxic T lymphocyte (CTL) targeting said peptide； and a method for inducing the antigen-presenting cell or the CTL. Furthermore, the present invention provides a composition and a pharmaceutical composition which include the peptide, the polynucleotide, the antigen-presenting cell, and the CTL as active ingredients. Moreover, the present invention provides a method which uses the peptide, the polynucleotide, the antigen-presenting cell, the CTL, or the pharmaceutical composition to treat and/or prevent cancer, and/or prevent the postoperative recurrence of cancer. Also provided is a method for inducing an immune response against cancer.本發明提供具有細胞毒性T細胞誘導能力之來自MPHOSPH1的抗原決定位胜肽。本發明並提供編碼為該胜肽之多核苷酸、呈現該胜肽之抗原呈現細胞及誘導以該胜肽為標靶之細胞毒性T細胞、及該抗原呈現細胞或該CTL之方法。本發明更提供包含以該等作為有效成分之組合物及藥學組合物。本發明更提供使用本發明之胜肽、多核苷酸、抗原呈現細胞、細胞毒性T細胞、或本發明之藥學組合物來治療及/或預防癌，及/或預防術後之癌再發之方法。又，提供誘導對於癌之免疫反應之方法。
